TN2018000318A1 - Abiraterone acetate formulation and methods of use. - Google Patents

Abiraterone acetate formulation and methods of use.

Info

Publication number
TN2018000318A1
TN2018000318A1 TNP/2018/000318A TN2018000318A TN2018000318A1 TN 2018000318 A1 TN2018000318 A1 TN 2018000318A1 TN 2018000318 A TN2018000318 A TN 2018000318A TN 2018000318 A1 TN2018000318 A1 TN 2018000318A1
Authority
TN
Tunisia
Prior art keywords
methods
abiraterone acetate
acetate formulation
formulation
compositions
Prior art date
Application number
TNP/2018/000318A
Inventor
Satya Bhamidipati
H Bosch
Matthew Callahan
Jason Coleman
Christopher Hill
Maura Murphy
Paul Nemeth
Marck Norret
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2018000318(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of TN2018000318A1 publication Critical patent/TN2018000318A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
TNP/2018/000318A 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use. TN2018000318A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
TN2018000318A1 true TN2018000318A1 (en) 2020-01-16

Family

ID=55533897

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP/2018/000318A TN2018000318A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use.
TN2017000098A TN2017000098A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TN2017000098A TN2017000098A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use.

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102617537B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2018000318A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016162229A1 (en) 2015-04-10 2016-10-13 Capsugel Belgium N.V. Abiraterone acetate lipid formulations
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
WO2020151633A1 (en) * 2019-01-25 2020-07-30 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
EP3935068B1 (en) 2019-03-06 2023-09-06 Propella Therapeutics, Inc. Abiraterone prodrugs
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
IL297990A (en) * 2020-05-08 2023-01-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
EP4291159A1 (en) 2021-02-15 2023-12-20 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141013B2 (en) * 2009-04-24 2017-06-07 イシューティカ ピーティーワイ リミテッド Production of encapsulated nanoparticles on a commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009436A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
CN102743393A (en) 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
TWI686212B (en) 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 Abiraterone acetate formulation

Also Published As

Publication number Publication date
BR112017003219A2 (en) 2017-11-28
AP2017009804A0 (en) 2017-03-31
SG11201701139YA (en) 2017-03-30
KR20170070025A (en) 2017-06-21
MX2017003525A (en) 2017-06-21
CN106687112A (en) 2017-05-17
KR20230014878A (en) 2023-01-30
JP2017528457A (en) 2017-09-28
EP3193857A1 (en) 2017-07-26
PH12017500239A1 (en) 2017-07-03
TN2017000098A1 (en) 2018-10-19
KR102491439B1 (en) 2023-01-25
KR102617537B1 (en) 2023-12-22
AU2015317466A1 (en) 2017-02-23
IL250270A0 (en) 2017-03-30
WO2016044701A1 (en) 2016-03-24
MD20170048A2 (en) 2017-08-31
EP3193857A4 (en) 2018-04-11
CO2017002472A2 (en) 2017-07-11
IL250270B (en) 2021-02-28
CA2958316A1 (en) 2016-03-24
EA201790650A1 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
MX2023008693A (en) Modulatory polynucleotides.
RS65327B1 (en) Substituted indazoles, process for their preparation, pharmaceutical formulations containing them, and their use for the preparation of medicaments
EP3386484A4 (en) Compositions and methods for delivery of therapeutic agents
NZ712350A (en) Abiraterone acetate formulation
CA2956871C (en) Compounds active towards bromodomains
IL273300A (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
HK1246189B (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
TN2015000411A1 (en) Ceftolozane antibiotic compositions
EP3177286A4 (en) Compositions and methods for physiological delivery using cannabidiol
IN2014MU00303A (en)
EP3177271A4 (en) Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IN2014CH00840A (en)
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
MX2017001512A (en) Compounds active towards bromodomains.
GB201414271D0 (en) Composition for delivery of an active pharmaceutical substance and method of preparing same
MY180947A (en) Ceftolozane antibiotic compositions
IN2014CH01890A (en)